Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
AEGLEA BIOTHERAP RG (NQ: AGLE)
10.62 USD  +0.90 (+9.26%)
Official Closing Price  /  Updated: 8:00 PM EDT, May 25, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 211,732
Open 9.740
Bid (Size) 4.150 (100)
Ask (Size) 12.69 (1000)
Prev. Close 9.720
Today's Range 9.690 - 10.94
52wk Range 2.810 - 11.35
Shares Outstanding 21,858,874
Dividend Yield N/A
Performance
YTD
+97.40%
+97.40%
1 Month
+28.26%
+28.26%
3 Month
+66.98%
+66.98%
6 Month
+148.71%
+148.71%
1 Year
+123.58%
+123.58%
Top News
More News
Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference
Company to Webcast Presentation on Tuesday, May 22 at 8:30 a.m. ET Read More
from GlobeNewswire News Releases
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... Read More
from GlobeNewswire News Releases
More News
Read More
Aeglea BioTherapeutics Prices Public Offering of Common Stock
from GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
from GlobeNewswire News Releases
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
from GlobeNewswire News Releases
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
from GlobeNewswire News Releases
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
from GlobeNewswire News Releases
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
from GlobeNewswire News Releases
Aeglea BioTherapeutics Appoints Dr. Ivana Magov?evi?-Liebisch to Board of Directors
from GlobeNewswire News Releases
Benzinga's Top Analyst Calls From April 24, 2018
category BP , AGLE , Benzinga , and 8 more.
from Benzinga
Benzinga Pro's 5 Stocks To Watch Today
category AGLE , Trading Ideas , Pre/Market Outlook , and 9 more.
from Benzinga
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial